MD Anderson Cancer Center

Site:	MD Anderson Cancer Center	Go to their website
Address:	1505 Holcombe Blvd.
City:	Houston
State:	TX
Zip:	77030
Country:	USA

55 trials at this site

Phase	Trial [asc]	Trial Status	Site Status	Drug	NCT#
1	A First-in-human (FIH) Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) [Study ID: StrateGIST1]	Recruiting	Active	IDRX-42	NCT05489237
1	A Multiple Ascending Dose Study of R1507 in Children and Adolescents With Advanced Solid Tumors	Ongoing, but not recruiting	Closed	R1507	NCT00560144
1	A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer	Ongoing, but not recruiting	Closed	BEZ235	NCT00620594
2	A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors	Ongoing, but not recruiting	Closed	MEK162 + BYL719	NCT01449058
1	A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies	Active, not recruiting	Closed	QINLOCK Ripretinib DCC-2618	NCT02571036
3	A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib (intrigue)	Active, not recruiting	Active	QINLOCK Ripretinib DCC-2618 SUTENT Sunitinib	NCT03673501
1	A Study of NB003 in Patients With Advanced Malignancies	Recruiting	Active	NB003	NCT04936178
1	A Study of XmAb®18087 in Subjects With NET and GIST	Active, not recruiting	Closed	XmAb18087	NCT03411915
1	A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients	Ongoing, but not recruiting	Closed	BKM120 + GSK1120212	NCT01155453
2	A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST	Completed	Closed	Imatinib + AT13387	NCT01294202
1	A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors	Terminated	Closed	Trametinib + Palbociclib	NCT02065063
1	Administration of BIIB028 to Subjects With Solid Tumors	Ongoing, but not recruiting	Closed	BIIB028	NCT00725933
2	Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)	Recruiting	Active	Belzutifan	NCT04924075
1	Continuous Dosing of Regorafenib in Patients With Advanced Malignancies	Ongoing, but not recruiting	Closed	Regorafenib (BAY 73-4506)	NCT01117623
2	Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib	Completed	Closed	Dovitinib	NCT01831726
1	DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumor (GIST)	Active, not recruiting	Closed	DS-6157a	NCT04276415
3	Efficacy and Safety of AMN107 Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib (ENEST)	Completed	Closed	Nilotinib	NCT00471328
3	Efficacy and Safety of AMN107 Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib - Extension	Completed	Closed	Nilotinib	NCT00488150
2	Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST) (Novartis CSTI571BUS282)	Completed	Closed	Imatinib	NCT00867113
	Gastrointestinal Stromal Tumors (GIST) Registry	Completed	Closed	None	NCT00507273

MD Anderson Cancer Center

55 trials at this site

Page 1 of 3 | Next | Last